Becker’s asked C-suite executives from hospitals and health systems across the U.S. to share their organization’s areas of growth for the next few years.
Category: Static
13 executive appointments at CommonSpirit in 2023
Chicago-based CommonSpirit Health, led by Wright Lassiter III, is a nonprofit, Catholic health system that operates 142 hospitals and more than 2,200 care sites in 24 states.
Pioneering sports cardiologist, Mass General heart director dies at 86
Adolph “Dolph” Hutter Jr., MD, a globally renowned cardiologist and former director of Massachusetts General Hospital Heart Center’s cardiac performance program, died Dec. 5 at 86 of natural causes.
House passes the Lower Costs, More Transparency Act
On the evening of Dec. 11, the U.S. House voted in favor of moving The Lower Costs, More Transparency Act forward.
Burnout climbs its way to boards
Board members are a professional group less often linked to the chronic exhaustion and emotional fatigue of burnout. But governing bodies are now increasingly feeling the strain, Fortune reports.
Patients evacuated after parking garage fire at Mass General hospital
Patients were evacuated and several transported to other hospitals after a car fire broke out in a parking garage at Mass General Waltham (Mass.), ABC affiliate WCVB reported Dec. 11.
Penn Med exec eyed for interim university president, replacing Magill
A top executive with Penn Medicine is one possibility to replace the University of Pennsylvania’s president, who resigned Dec. 9.
WVU Medicine confirms inpatient C. auris case
A patient at a WVU Medicine facility has tested positive for Candida auris, a spokesperson for the Morgantown, W.Va.-based health system confirmed to CBS affiliate WDTV Dec. 8.
The street drug alarming physicians that's 10x more potent than fentanyl
Nitazenes, a group of highly potent, synthetic drugs made in the 1950s as opioid analgesics, are becoming more commonly used in street drugs. In some cases, it can even be 10 times more potent than fentanyl.
Novartis reports success in phase 3 trial of drug for rare kidney disease
Pharmaceutical maker and biotechnology company Novartis is reporting positive topline results from a phase 3 trial of a drug to treat a rare kidney disease.
